190 likes | 385 Views
The Construction of Mutations in the 3 Cyclization Sequence of Dengue Virus Genome, for the Study of Translation. Tari Tan Dr. Theo Dreher Dr. Connie Bozarth HHMI, Summer 2005. The Global Impact of Dengue Virus. Dengue Fever & Dengue Hemorrhagic Fever. Endemic in more
E N D
The Construction of Mutations in the 3 Cyclization Sequence of Dengue Virus Genome, for the Study of Translation Tari Tan Dr. Theo Dreher Dr. Connie Bozarth HHMI, Summer 2005
The Global Impact of Dengue Virus Dengue Fever & Dengue Hemorrhagic Fever Endemic in more than 100 countries 50 million cases each year Areas infested with Aedes aegypti Areas with Aedes aegypti and dengue epidemic activity
Dengue: Viral Properties • Flavivirus Genome Ranges from 10-11 kilobases 5' nucleotide cap +ssRNA • Serotype 2 (DEN-2)
Translation • DEN-2: +ssRNA • Viral Proteins are responsible for replication, assembly, maturation, and exit from the cell
Conserved Features Dumbbells 1 and 2 (DB1, DB2) Stemloops A and B (SLA, SLB) 5' Cyclization Sequence (cCS1) 3' Cyclization Sequence (CS1)
Kunjin Virus, observed effect of cCS1 and CS1 mutations on replication 3' mutant - no replication 5' mutant - no replication Deletion of cCS1 - no replication 5'+3' mutant restoring complementarity - delayed start, but efficient replication DEN-2, effect of cCS1 and CS1 mutations on translation Replace cCS1 with modified CS1 - little impact (efficient translation) Replace CS1 with modified cCS1 - only 19% translation 5'+3' mutant restoring complementarity - could not rescue translation Previous Studies Dr. Alexander KhromykhWei Wei Chiu
Five Mutations 1) IS TRANSLATION SEQUENCE-SPECIFIC FOR CS1? 2) Does the degree of complementarity between cCS1 and CS1 affect translational efficiency?
Definitions The DEN-2 construct into which the mutated sequences are ligated The fragment (or, in general terms, the DEN-2 construct containing the fragment) containing the mutated CS1, which is ligated into the vector The resultant vector+insert construct containing the mutated CS1 Vector Insert Mutant/Variant
Methodology • DCLD WT (insert); DCLD ∆DB1+2(vector)
Methodology (Cont.) • PCR amplification of mutated sequences, using DCLD WT
Methodology (Cont.) • Digest Final PCR product with Hind III and Kpn I; isolate 474 bp fragment • Insert mutants into DCLD ∆DB1+2 (which has already been digested with Hind III and Kpn I) via a ligation • Ultimately, the mutants will be used to assess translation by measuring luciferase luminescence
Troubleshooting First PCR Purify Megaprimer Second PCR Hind III/Kpn I Digest Purify Fragment Ligation with DCLD ∆DB1+2 Grow/Prep Colonies Hind III/Kpn I Digest (Select) Send For Sequencing PCR - poor yield Digests - not cutting Liquid Cultures - not growing / no plasmid
Annealing Temperature/ Mg2+ concentration • New Oligos 60o C 2 1.5 .75 mM mM mM 65o C, 1.5 mM MgCl2 2nd PCR, Khromykh (DCLD-SnaB1/Not1 template, WW12 + Khromykh megaprimer) 2nd PCR, A-Rich (DCLD-SnaB1/Not1 template, WW12 + A-Rich megaprimer) D K L S 137 bp 128 bp K Gel-pure Megaprimers, (3 ul/ 30) 479 bp Final PCR product, “K” mutant PCR Modification
Diagnostic Digests • Performed by Dr. Bozarth BUFFERS Buffer R (HindIII buffer) Buffer KpnI HindIII ENZYMES KpnI
NH2 H Ampicillin N O ß -lactam H NH CH3 S O CH3 N OH O O Bacterial Growth
Liquid Cultures & Loss of Plasmid Plate Investigation • Hard-to-clone sequences? • Mutants toxic to cells?
∆DB 1+2 DCLD Phosphatased, phenol-extracted, EtOH precipitated, gel-pure vectors (digested with Hind III and Kpn I) Vector Reconstruction • Problem with the vector? • Make ∆DB1+2, as well as DCLD
I. PCR - poor yield Annealing Temperature: 60o C MgCl2 Concentration: 1.5 mM Re-designed oligos to be shorter: better yield II. Digests - not cutting Dr. Bozarth’s Trials: bad KpnI or Buffer KpnI (bought new enzyme and buffer) III. Liquid cultures not growing / Loss of plasmid DCLD as control: only controls grew (2 x YT not the problem) Streaking: selective growing, but still problems in liquid cultures Re-make vector, both ∆DB 1+2 and DCLD: under investigation These issues remain unresolved. Summary
Acknowledgements • HHMI - Dr. Kevin Ahern • URISC • Dr. Theo Dreher • Dr. Connie Bozarth • Everyone else in the Dreher lab for helping me out Thank you very much!